Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

582

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: Datopotamab Deruxtecan

Sponsor

AstraZeneca

Collaborators

[object Object]